intranasal zavegepant
Preclinical
intranasal zavegepant is one of 38 therapeutic programs targeting Migraine. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
102 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cervidil
PfizerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine1 trial
A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of Migraine
Not yet recruiting·AAmerican Center for Psychiatry and Neurology·Preclinical·NCT07861412·250 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for intranasal zavegepant. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]